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1. Introduction 
The treatment of cancer is generally based on histological grade, respectability and the 
presence or absence of metastasis. Because interventions after the manifestation of 
metastasis are notoriously ineffective for most cancers, great effort is invested in the 
development of targeted therapies to eradicate or suppress the growth of cancer. A complete 
understanding of the cancer process requires more detailed knowledge of the mechanisms 
maintaining neoplastic growth and it is is a prerequisite not only for understanding the 
genesis of human cancer but also for the identification of molecular events responsible for 
cancer maintenance. New drugs must be designed against the mechanisms that are 
responsible for cancer maintenance not for the initial event that transform a normal cell into 
cancer cell, because it is possible that the first alteration of the cancer cell will have no 
function in the subsequent steps of cancer development. Much effort is currently being 
expended to target the mutated oncogenes and tumour suppressor genes that control 
neoplastic cell growth directly. Inactivation of oncogene(s) can cause cancer remission, 
implying that oncogenes are the Achilles' heel of cancers. This current "hands on" model of 
cancer has kept oncogenes firmly in focus as therapeutic targets and is in agreement with 
the fact that in human cancers all cancerous cells, with independence of the cellular 
heterogeneity existing within the tumour, carry the same oncogenic genetic lesions. 
However, many of the new classes of agents targeting the oncogenes usually do not show a 
permanent clinical benefit. These clinical observations suggest that oncogene-induced 
tumourigenesis is not reversible through the unique inactivation of the gene defect(s) 
initiating cancer development. But, what are the mechanisms of tumor relapse by which 
tumors evolve to escape oncogene dependence? Several recent studies of the effect of 
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oncogenes in stem cells in cancer development (Barker et al., 2009; Perez-Caro et al., 2009; 
Zhu et al., 2009; Bussard et al., 2010; Jacques et al., 2010; Nakagawa et al., 2010; Saring et al., 
2010; Zhang et al., 2010) implicate that tumor reprogramming (where the maintenance of 
oncogene expression is not critical for the generation of differentiated tumor cells) might 
represent a potentially important mechanism of tumour development for many types of 
cancer and that, if this is the case, the oncogenes that initiate tumor formation might be 
dispensable for tumor progression and/or maintenance. The practical implications that this 
new point of view has for the therapy of cancer are obviously enormous (Castellanos et al., 
2010). This chapter addresses the impact of these results toward a better understanding of 
carcinogenesis and proposes research avenues for tackling these issues in the future. 
2. The cancer stem cell (CSC) concept 
The cancer stem cell (CSC) theory hypothesizes that a cancer maintains a hierarchical 
organization similar to a normal tissue. Thus, the tumor mass is the result of 
differentiated progeny of rarer CSCs with self-renewal capacity (Sanchez-Garcia et al., 
2007). Chronic myeloid leukemia (CML) is universally regarded as providing the 
strongest evidence in support of the CSC concept. Fialkow and his colleagues first 
suggested that CML arose from rare transformed hematopoietic stem cells (HSC) nearly 
40 years ago, when they showed that both granulocytes and red blood cells from CML 
patients were derived from a common cell (Fialkow et al., 1977). However, the term 
tumor/cancer stem cell was first coined nearly 40 years ago to highlight the observation 
that only a minority of multiple myeloma cells were capable of clonogenic growth 
(Hamburger and Salmon, 1977). The last decade has witnessed an increasing re-
appreciation of the role of these heterogenous cellular cues in cancer development and 
therapy. This re-evaluation represents a rather crucial detour from the widely held view 
that the neoplastic phenotype resulted from uncontrolled proliferation of tumor cells. The 
CSC concept would explain not only the low clonogenic capacity of most malignancies, 
but also why complete treatment responses translate into cures in only a minority of 
cancer patients. Initial responses in cancer represent therapeutic effectiveness against the 
bulk cancer cells, while rarer resistant CSCs could be responsible for relapse. Accordingly, 
improving the results of cancer therapy would require identification and better 
understanding of the biology of CSC (Perez-Caro et al., 2009; Saito et al., 2010) (Figure 1).  
Within this framework, fundamental determinants of neoplastic disease are to be found 
within the CSC and, thus the role of CSC regarding cancer biology, management and 
therapy needs to be evaluated (Sanchez-Garcia, 2009). It should be noted that partial tumor 
responses to therapy mean little if CSCs are the major cells determining outcome (Sanchez-
Garcia, 2009). Because of the difficulty of assessing the effects of therapies on the rare CSCs 
responsible for cancer maintenance and relapse, the development of new clinical approaches 
will require new clinical paradigms and methodologies that should rely heavily on 
preclinical modelling, using novel preclinical assays to evaluate the fate of CSC (Sanchez-
Garcia et al., 2007) Preclinical studies should assess the effects of therapies on CSC and 
differentiated cancer cell populations. This could allow us to take directly to the patient a 
fully functional new approach (Figure 1).  
A related concept is that the exact definition of “stemness” is elusive and stemness may be 
more of a cotinuum or a property that may be regained in cancer, which would suggest that 
neither the hierarchical nor the stochastic model are exclusively right. 
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Furthermore, we must call the attention to the fact that the fundamental concept essential to 
the CSC hypothesis does not have anything to do with the absolute frequency of these cells 
within the tumour; indeed, what the model states is that there is a functional heterogeneity 
within the tumor cellular components, and that there is only a defined population of cells that 
can initiate/maintain malignant growth in vivo while the remaining cells cannot. Thus, the 
therapeutic implications of the CSC concept are equally important whatever their frequency is 
within each tumour type: they are the cells that must be effectively targeted to achieve a 
definitive cure on the long round (Perez-Caro et al., 2009; Saito et al., 2010) (Figure 1).  
3. Stem cells and cancer initiation 
The nature of the cell in which the initiating mutation occurred in human cancer has 
received little attention during the last decades. Since the process of carcinogenesis need to 
accumulate a number of oncogenic events during long periods of time, only cells with self-
renewal capacity, would be in the tissue enough time to accumulate the oncogenic 
alterations necessary for the complete cell transformation. This fact seems to be particularly 
evident, in tumors originated in tissues with high cellular turnover, as the skin, the intestine 
or the breast, where normal stem cells should be the target for the oncogenic initiation event 
(Al-Hajj et al., 2003; Singh et al., 2004; Wang et al., 2009; Jacques et al., 2010). For more 
differentiated cells to originate epithelial cancer, it would be necessary that the first 
oncogenic event to induce a fully tumor phenotype, or at least be able to trigger a partial 
stem cell-like program that permit the differentiated progenitor to acquire surviving and 
self-renewal capabilities, and probably new adhesion properties near the basal membrane to 
avoid being expelled from the tissue under the normal cellular turnover. In recent years, 
there is growing evidence that stem cells are the cells of origin for several types of cancer 
(Sanchez-Garcia et al., 2007; Vicente-Dueñas et al., 2009). An example is provided by the 
chronic myelogenous leukaemia (CML), a granulocytic disease (Melo and Barnes, 2007). 
However, the BCR-ABL translocation, pathognomonic of this disease, does not arise in a 
granulocyte, but rather in a cell at the beginning of the hematopoietic differentiation tree 
(Jamieson et al., 2004).  
4. Caveats for identification of CSC in human cancer 
In human cancer the definition of the identity of CSCs comes from experiments of serial 
transplantation of flow cytometry-sorted cell populations into immunocompromised mice. 
The CSC-containing population should recapitulate the cellular heterogeneity present in the 
primary human cancer and must have the capacity for self-renewal on serial passaging 
(Cobaleda and Sanchez-Garcia, 2009). However, there are many technical issues concerning 
the isolation and determination of CSC capabilities from human cancer samples, ranging 
from the methods of selection of the cells themselves to the choice of the recipient animals 
where the cells can reveal their potential and to the injection site within the recipient 
(Cobaleda and Sanchez-Garcia, 2009). To avoid these caveats an alternative way to study the 
CSC population is to use mice as a system model. 
5. Identification of CSC in mouse models of human cancer 
Much of our current conceptualization of how tumorigenesis occurs in humans is strongly 
influenced by mouse models of cancer development (Perez-Losada et al., 2002; Sanchez-
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Martin et al., 2002; Perez-Mancera et al., 2005a; Perez-Mancera et al., 2005b; ). But studies in 
mice in which the oncogenic alteration(s) is not directed to the specific cells of origin, as it 
normally occurs in most current mouse models, should be interpreted cautiously (Vicente-
Dueñas et al., 2010)  
The genetic alterations found in human cancer seem to occur during specific periods of time 
and restricted to a few specific cells. In several cases, like in the case of CML, the cancer cell-
of-origin is a stem/progenitor cell, and this explains the stem properties that allow the CSCs 
to maintain the tumor mass. However there are also many cancers where most probably the 
cancer cell-of-origin would be a more differentiated cell (Cobaleda et al., 2007). In these 
cases, the combination of the reprogramming capabilities of the oncogenic alteration and the 
intrinsic plasticity of the target cell (i.e., its susceptibility to the reprogramming) determine 
the final outcome of a CSC. Since not all the cells present the same susceptibility to 
reprogramming, and not all the oncogenes posses the same reprogramming capacities (i.e., 
the ability to confer stem cell features to the target cell), the targeting of the oncogenic 
alteration to the wrong cellular compartment is a likely cause of failure in the generation of 
accurate mouse models of human cancer. Considering these facts, three independent groups 
have already shown that the genotype-phenotype correlations found in human cancer can 
be established in mice by specific targeting of stem cells (Barker et al., 2009; Perez-Caro et 
al., 2009; Zhu et al., 2009). 
6. Cancer as a reprogramming-like disease  
In a normal stem cell-driven tissue, genetic programming of stem cells is all what is required 
to (re)constitute all differentiated cells forming the tissue and the genetic information 
responsible for the stem cell programming is not anymore expressed within the 
differentiated cells that form the tissue. As we have mentioned before, in the last years, 
many evidences have been accumulated indicating that cancers are also hierarchically 
organized tissues which can be created and maintained like a normal stem-cell-based tissue 
(Etzioni et al., 2003; Sanchez-Garcia et al., 2007; Jemal et al., 2009).  The most challenging 
arena in which to prove this concept are those tumors whose main cellular components are 
terminally differentiated cells. A clear example of this kind of tumors is the chronic phase of 
CML. To elucidate if CML is a stem cell-driven tissue, we developed mice limiting BCR-ABL 
expression to the Sca1+ cells (Sca1-BCRABL mice) (Sanchez-Garcia et al., 2009). Thus, our 
Sca1-BCRABL is a very suitable in vivo model to study the consequences of ectopic 
expression of BCR-ABL targeted to stem cells. However, in human CML and in most animal 
models of cancer, the oncogenic alteration(s) is(are) present in all the cellular types that 
compose the tumoral tissue, from the cancer cell-of-origin to the terminal differentiated 
granulocytes.  In our stem cell-driven Sca1-BCRABL model, the expression of the oncogene 
is restricted to the stem/progenitor compartment but is nevertheless capable of generating a 
full-blown CML with all its differentiated cellular components. Of course, the 
demonstration that CML development can be established in mice by limiting oncogene 
expression to Sca1+ cells implies that abolishing oncogene function does not interfere with 
the formation of differentiated tumor cells, and suggest that the oncogene imposes a gene 
regulatory state in stem cells that somehow persists during hematopoiesis and which 
imposes a tumor phenotype reflective of the usual CML, an observation that seems to apply 
to other cancer-initiating gene defects (Sanchez-Garcia et al., 2009). Therefore, we 
hypothesize that the oncogene mediates tumorigenesis through epigenetic/genetic 
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modification of target genes that remain in this modified state in the mature tumor even in 
the absence of BCR-ABL in agreement with a reprogramming role for BCR-ABL in regulating 
CML formation. Supporting these observations, it has been recently shown that only stem 
cells, but not astrocytes, gave rise to brain tumors, independently of their location. This 
suggests a cell-autonomous mechanism that enables stem cells to generate brain tumors, 
underlining an important role of stem cells and the relevance of initial genetic mutations in 
the pathogenesis and phenotype of brain tumors. 
 
 
Fig. 1. Approaches to target CSC. 
Recent breakthroughs have shown that reprogramming of differentiated cells can be 
achieved by the transient expression of a limited number of transcription factors that can 
“reset” the epigenetic status of the cells and allow them to adopt a new plethora of possible 
fates. Several of these reprogramming factors were previously known for their oncogenic 
activity, already connecting the role of oncogenes with tumoral cell fate reprogramming. 
Furthermore, it has recently been shown that the elimination of p53, whose function is to 
prevent the survival and expansion of cells with genetic damage, greatly enhances the 
reprogramming efficiency in the generation of induced pluripotent cells (iPS) (Castellanos et 
al., 2010). These p53-null reprogrammed cells carry, however, several types of mutations 
(Castellanos et al., 2010). These results confirm the fact that the absence of the tumor 
suppressor does not have an instructive role in tumorigenesis, but just a permissive one, so 
p53 would prevent cells with damage from being successfully terminally reprogrammed. 
This indicates that the driving force of the reprogramming process are the reprogramming 
factors themselves, and that just the necessity of maintaining genetic integrity prevents the 
reprogrammed cells with any kind of damage to progress along the newly programmed 
pathway. As a logical consequence, it has recently been proposed that cancer stem cells 
might arise through a reprogramming-like mechanism and that, if this is the case, perhaps 
the oncogenes that initiate tumor formation might be dispensable for tumor progression 
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(Castellanos et al., 2010). Further to this, it has also been shown in the haematopoietic and 
nervous systems that the susceptibility of cells to reprogramming is inversely proportional 
to their degree of differentiation, and that hematopoietic stem cells (HSC) are 300 times 
more prone to be reprogrammed than B or T cells (Castellanos et al., 2010). Our results show 
that this stem cell reprogramming is indeed possible in the case of BCR-ABL. But perhaps 
the most crucial question is whether these hands-off regulation mechanisms can be found in 
other cancer types, especially tumors of epithelial origin, which represent the bulk of human 
cancers. Importantly, a small subset of Sca1-BCR-ABL mice develops additional solid 
tumors. Considering that Sca1 has been identified as a almost universal stem cell marker in 
many different tissues, these data would suggest that the view of cancer as a 
reprogramming-like disease is not specific to only hematopietic tissues, but rather 
represents a broader mechanism for deregulation of stem cell differentiation, providing a 
paradigm that can be applied to solid-organ cancers and, together with all the above 
discussed findings, provide enough experimental evidence to support the view of cancer as 
a reprogramming-like disease (Castellanos et al., 2010). 
This model of cancer (Figure 1) is very informative with respect to the fact that the 
oncogenic mutations can have different roles in CSC versus differentiated cancer cells, and 
explains why targeted therapies like imatinib can eliminate the latter without affecting the 
former. However, we should be cautious in interpreting the data as a mimicking of human 
disease as mouse cells are more prone of transformation than human cells and thus one 
mutation can lead to full blown cancer in the mouse transgenic model but not in human. 
Furthermore, the regulation of certain genes/pathways might differ between mouse and 
human.  
There are many evidences now suggesting that human cancer could be considered as a 
reprogramming-like disease. If the potential growth of cancer depends on CSCs and on 
oncogenes that can function in a hands-off manner, it would be important to know how to 
eradicate these cells and/or inactivate the reprogramming mechanism (Castellanos et al., 
2010) (Figure 1). 
7. Conclusions  
There are many evidences now suggesting that human cancer could be considered as a 
reprogramming-like disease (Castellanos et al., 2010). If the potential growth of cancer 
depends on CSCs and on oncogenes that can function in a hands-off manner, it would be 
important to know how to eradicate these cells and/or inactivate the reprogramming 
mechanism (Figure 1). The coming years will show whether this optimism is well founded, 
or whether the immense complexity of this disease will continue to confound our best 
endeavours to tackle cancer. 
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